Kenvue Surges as Earnings Beat, Kimberly-Clark Merger Gains Steam

Stock Market Today, Feb. 18: Kenvue Rises After Earnings Beat Expectations

Kenvue (NYSE:KVUE), maker of consumer health products including Tylenol, Neutrogena, and Listerine, closed Wednesday at $18.88, up 2.55%. The stock moved higher after Q4 results beat expectations and analysts raised price targets, while investors are watching progress on the pending Kimberly-Clark (NASDAQ:KMB) acquisition and related restructuring plans.Trading volume reached 46.9 million shares, coming in roughly 3.9% above its three-month aver…

Kenvue Surges as Earnings Beat, Kimberly-Clark Merger Gains Steam

Quick Read Kenvue (KVUE) beat Q4 estimates with adjusted EPS of $0.27 versus $0.22 expected. Revenue of $3.78B topped consensus. Kenvue’s $48.7B acquisition of Kimberly-Clark (KMB) received shareholder approval and expects to close in H2 2026. Kenvue announced a 3.5% workforce reduction with $250M in restructuring charges ahead of merger integration. Are you ahead, or behind on retirement? SmartAsset's free tool can match you with a financia…

Better-Than-Expected Quarter For Kenvue; Announces Job Cuts Head Of Kimberly-Clark Deal

Kenvue, the consumer health products firm set to be acquired by Kimberly-Clark, has beaten Wall Street estimates for fourth-quarter results and announced plans to reduce its workforce worldwide. The US firm, which was spun off from Johnson & Johnson in (more…) The post Better-Than-Expected Quarter For Kenvue; Announces Job Cuts Head Of Kimberly-Clark Deal appeared first on KamCity.